Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 58.15 -0.69 (1.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.84 | 52 Week High | $8.22 | |||
| Open | $58.06 | 52 Week Low | $3.07 | |||
| Day High | $59.90 | P/E | N/A | |||
| Day Low | $56.97 | EPS | $-1.30 | |||
| Volume | 583,467 | |||||
